[Skip to Content]
[Skip to Content Landing]
December 1964

Myeloproliferative SyndromeEvaluation of Myelosclerosis and Chronic Myelogenous Leukemia to Polycythemia Vera

Author Affiliations


From the Department of Clinical Hematology, Blood Center, Division of Medicine, Michael Reese Hospital and Medical Center, and the Department of Medicine, Chicago Medical School.; Senior Resident in Internal Medicine, Michael Reese Hospital and Medical Center (Dr. Lopas); Director, Blood Center, Michael Reese Hospital and Medical Center, and Associate Professor of Medicine, Chicago Medical School (Dr. Josephson).

Arch Intern Med. 1964;114(6):754-759. doi:10.1001/archinte.1964.03860120066004

Introduction  Several authors 2-4,12 have theorized that a whole host of clinical entities, grouped under the title of "myeloproliferative syndrome," have a common pathogenesis and perhaps a common etiology. The clinical entities usually included under the title of "myeloproliferative syndrome" are myelofibrosis with myeloid metaplasia, polycythemia vera, chronic myelogenous leukemia, primary thrombocythemia, and the di Guglielmo syndromes. Some authors have speculated that certain lymphomas should also be included.3The evidence presented in favor of a unitary view of this group of illnesses usually consists of (1) the common ancestry, in the primitive multipotential mesenchymal cell, of the cell lines involved in the clinical entities listed; (2) the frequent observation of intermediate forms, that is, features characteristic for several of the clinical entities seen in the same patient; (3) the natural evolution of any one of these entities into one another.It is with respect to the last point that

First Page Preview View Large
First page PDF preview
First page PDF preview